Press Releases
CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued high response rate with favorable safety and tolerability profile observed in heavily pre-treated patients at 100mg BID Encouraging durable responses and progression free survival at 100mg BID Excerpt from the Press Release: CAMBRIDGE, Mass., Dec. 16, 2021…
Read MoreFirst Phase 2 combination trial results presented in oral session at 2021 ASH Annual Meeting Olutasidenib with azacitidine well tolerated with a safety profile largely consistent with olutasidenib alone Molecular characteristics of olutasidenib monotherapy response reported in ASH poster presentation Excerpt from the Press Release: WATERTOWN, Mass.–(BUSINESS WIRE)–Dec. 16, 2021– Forma Therapeutics Holdings, Inc.…
Read MoreHighly Versatile and Programmable RED PLATFORM Enables Multiple Modalities to Target Different Immune Pathways Across a Range of Diseases Demonstrated Tolerance Induction with Bystander Suppression in Type 1 Diabetes Preclinical Program with Findings Translatable to Multiple T Cell-Mediated Autoimmune Diseases Advancing Next-Gen Artificial-Antigen Presenting Cells (aAPCs) with Loadable MHC Class 1 Platform, Enabling Presentation of…
Read More– Microbiome data demonstrate the successful engraftment of SER-287 – – Microbiome assessments suggest potential for biomarker-based patient selection – – Company continues to evaluate SER-287 study data, and available preliminary SER-301 Phase 1b study clinical and microbiome data, to inform plans for continued development in ulcerative colitis – Excerpt from the Press Release: CAMBRIDGE,…
Read More~ Treatment was well tolerated with no significant safety issues related to AMT-130 in first two treated patients through one year of follow-up ~ ~ Neurofilament Light Chain (NfL) rose as expected immediately following surgery andreturned to baseline in treated patients ~ ~ A total of 19 patient procedures have been performed in the U.S.…
Read MoreA retrospective comparative study confirmed that both vaccines provide strong protection against symptomatic SARS-CoV-2 infection. Excerpt from the Press Release: CAMBRIDGE, Mass., Dec. 15, 2021 /PRNewswire/ — nference, the AI-driven health technology company, announced today publication of a peer-reviewed study in Med that analyzed Mayo Clinic based data with nference artificial intelligence (AI) software to…
Read MoreData from preclinical studies in collaboration with Fred Hutchinson Cancer Research Center will be presented at ASH and provide strong rationale for use of EOS-448 as a single agent and in combination with an immunomodulatory drug in patients with multiple myeloma Preclinical data shared at TIGIT Therapies Digital Summit highlight evidence for multifaceted mechanism of…
Read MorePreclinical pseudovirus data and structural modeling shows ABP 310 retains activity and potency against the SARS-CoV-2 Omicron variant mutations ABP 310 EUA possible as early as 2022 Excerpt from the Press Release: WOBURN, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) — Abpro Corporation, a clinical stage biotechnology company developing next-generation antibody therapies, today shared an assessment of…
Read MoreNew DESTINY-Breast03 data presented at SABCS 2021 showed AstraZeneca and Daiichi Sankyo’s ENHERTU demonstrated a similar benefit in patient subgroups, including in patients with stable brain metastases, versus T-DM1 Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–New results from the DESTINY-Breast03 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki)demonstrated a higher progression-free survival (PFS) and objective…
Read MorePartnership for Accelerating Cancer Therapies to conduct extensive biomarker analysis for ongoing phase 2 clinical trial in non-small cell lung cancer Trial combines CAN-2409 with immune checkpoint inhibitor treatment after inadequate tumor response to initial checkpoint inhibitor therapy Collaboration may identify early markers of response and inform patient selection for treatment Excerpt from the Press…
Read More